Capital Cell

MainImage

124,714.65€

Out of 125,000.00€

investors

49

Est. ROI

825%

days left

--

Invest in Capital Cell´s growth

Finish date: 01/01/1970 Barcelona

Premoney valuation

1,000,000.00€

Percentage offered

11.11%

Est. ROI

825%

Exit horizon

2021

The project

Capital Cell is the first European equity crowdfunding platform specialised in Biotech and the Life Sciences.  It is a platform that lets you buy shares in Life Science companies, starting at low entrance tickets. 

Capital Cell gets entrepreneurs in need of funding in touch with investors, professional or not, who want to invest their money in projects with a high growth potential. Equity crowdfunding is a financial system through which a large number of individuals can fund a company, starting from very low amounts. In addition, we only offer projects validated by our scientific committee, and we offer a simple and secure system with astandarised legal procedure so that investment is easy and straightforward.

Capital Cell was born in early 2015, and it already closed 4 campaigns, raising €530.000, among which: 

In addition, the team behind Capital Cell is responsible for Spain's largest crowdfunding campaign, "El Español" by Pedro J. Ramírez:

Business opportunity

Biotechnology is the most profitable investment sector in Spain since 2008, and it is continuously growing. For instance, the MSCI World Biotech index has surged by 200% during the last 5 years, presenting the highest ROI among technology indexes.

While North America and Asia are embracing crowdfunding as a practical tool to help fund businesess, including those in Life Sciences, Europe is still below those markets in total crowdfunding investment. At the same time, many European life sciences companies, especially those in countries like Spain, struggle to find the funding they need, particularly in its earlier stages. .

Equity crowdfunding was born in the United States in 2013, and it already raised almost $1 billion in 2014. In Europe, the sector took off in 2013. and in 2014 it raised €23M in general platforms - with a (projected) growth in 2015 of over 400%.

Capital Cell is the first European equity crowdfunding platform specialized in biotechnology and life sciences, and so we make a double bet on innovation, both from a scientific and from a financial point of view. We are making investment in biotech startups easy and accessible for a much wider range of potential investors, and we are helping foster a fastly growing, highly profitable sector.

Investment & Exit

Capital Cell is already working on a €5M round in the United Kingdom, with te aim to make Capital Cell the reference investment platform for biomedical companies in Europe, and we are already negotiating with two Asian investment funds. 

This round is being raised through David Orchard (WGP Global) and Alan Barrell (Judge Business School), under success fee conditions.

The current round

We are looking for investors for a bridge round of 125.000€ that helps us: 

  1. reinforce our position as a CNMV-supervised platform 
  2. develop a more functional technological platform
  3. invest in marketing

 

Lead Investors

The round is led by Xavier and Josep Castells,  CFO and CEO at Inkemia - IUCT respectively, who provide Capital Cell with an enormous investment experience and the largest specialised investor network in Spain.  

Xavier Castells

Xavier Castells

Managing Director, IUCT Emprèn (investment division at Inkemia) 

CFO, Inkemia-IUCT (listed in the MAB, the Spanish alternative stock market)

 

 


Josep Castells

Josep Castells

PhD in Chemistry & founder of 6 ventures
Plasmia Biotech (2010 - currentl)
Inkemia IUCT Group (IUCT Corportion) (2010 - current)
IUCT Espais (2010 - current)
IUCT Empren (2010 - current)
IUCT s.a. (1997 - current)
Catalonia Internet Service Provider - CISP (1996-Sold in 2000)
 

Valuation

Since Capital Cell's investment round in the UK (its "Series A") is currently being negotiated, we currently cannot fix the company's value. Therefore, the investment is being done as a convertible equity loan, which will be converted to shares once the Series A is closed. The valuation will be the one decided then, with a 30% discount (as an indication, the valuation discussed for the series A is 3-5M). 

If the Series A didn't finally take place, the shares would be converted to a €1M PreMoney valuation, for a 11.11% of the company. 

Return of Investment

Capital Cell's plan is not to charge for its services in cash, but to keep shares in the companies funded through the platform, which means that in 5 years Capital Cell will have generated around €2.5M in profit, but it will also have a portfolio with shares in over 400 companies.

Return of investment for Capital Cell as a platform is approximately 400% in 5 years, but the projected value of the funded companies is over 800M. Return of investment would come through:

  • sale of Capital Cell to a financial, pharmaceutical or internet company 
  • exit from one of the participated companies
  • sale of the entire investment portfolio
  • and, most of all, you will be able to sell your shares in Capital Cell once its listed in London's stock exchange, starting 2018 

Summarising:

Investing 1 euro in Capital Cell today would bring back between 8.25 and 31.4 euros in 5 years*

* depending on the number of companies funded through Capital Cell that are successful 

Drivers

Daniel Oliver, Founder and Director

Biologist by the University of Barcelona, he has worked for multinational companies like Accenture, Merck or Mondial Assistance, both in Spain and in the UK. Founder of Creo en tu Proyecto, he managed the largest crowdfunding campaign in Spain. He's the current President at Crowdfunding Spain, member of the Board of Directors at the European Equity Crowdfunding Association (EECA) and advises the European Comission on Crowdfunding law.

Nigel Ten Fleming, Chairman of the Board

Chairman of G2B Pharma Inc., a company which he founded in 2008, and a member of the board of directors of Genmedica Therapeutics, a diabetes company based in Barcelona. He previously founded Athena Diagnostics, a neurological diagnostics reference laboratory, in various capacities, including Chairman, CEO and Vice President prior to the company’s 2011 sale to Quest Diagnostics, Inc. Dr. Fleming obtained his Ph.D. in Clinical Biochemistry from the University of Cambridge in England, completed a post-doctorate at Boston University School of Medicine and was a lecturer and researcher at Harvard Medical School from 1983 to 1989.

José Luis Minguez, Investor Relations

Over 24 years of experience in the chemical sector in a multinational company. Investor and "micro Business Angel" in over 50 European companies through equity crowdfunding. 

Mar Fumanal, Coordination

Psychology graduate, she holds extensive experience in business administration and team management. She has worked with technology-based startups. 

Pablo Valcárcel, Business Development

Law graduate and CEO at Geosophic. Lean startup expert and crowdfunding facilitator. 

Advisors

        

Taro Sato: board member, Taro Ventures

   

Alan Barrell: Cambridge Judge Business School

   

Albert Ventura: Satvas Lorien

 

Gabriel Masfurroll: Wings4Business, Clínica Tres Torres

 

Partners & Associates

                               

       

     

Product/Service

You can check our business plan (or at least a public draft) here:

Market

Crowdfunding is the fastest growing financial system in the world. In 2014 the sector moved $16.2 billion, a 270% growth from 2013's $6 billion. In Europe, the sector grew 144% on 2014, which surpassed every prediction. 

Equity crowdfunding is already a great source of funding for the life sciences sector in the United States. Healthiosxchange, for instance, who call themselves an "investment marketplace", has raised over $350 million for healthcare projects. Together with other platforms, over $1.3 billion have been raised for biotech through crowdfunding. In Europe, since 2014 more than 10 crowdfunding campaigns in life sciences have raised over 1 million euros, with the largest one raising over 2.6 million.

Roadmap

2015

- 4 successful Life Sciences rounds (total: 530K)
- Methods tested: we're the team behind the largest spanish CF campaign (3M)
- Investor base: 150
- Agreements with UAB, Keiretsu, Trifermed, Guano AG, VHIO, ACCIÓ, ...
- Sponsored by Generalitat de Catalunya
- Establishing connections with UK, Japan and US

Currently

- Registered with the CNMV (pending approval)
- Raising bridge round: 125K (led by Xavier & Josep Castells from Inkemia)
- Starting €5M round to internationalise Capital Cell, in talks with Asian investors
- Agreement with WGP Global (UK) to raise funds in UK

2016-2017

- The Leading pan-european Life Sciences investment platform
- Connections with international funds: China, US, Israel, ....
- Global resource center for Biotech investment
- IPO in the UK AIM market

Investment details

Capital Cell is already working on a €5M round in the United Kingdom, with te aim to make Capital Cell the reference investment platform for biomedical companies in Europe, and we are already negotiating with two Asian investment funds. 

This round is being raised through David Orchard (WGP Global) and Alan Barrell (Judge Business School), under success fee conditions.

The current round

We are looking for investors for a bridge round of 125.000€ that helps us: 

  1. reinforce our position as a CNMV-supervised platform 
  2. develop a more functional technological platform
  3. invest in marketing

 

Lead Investors

The round is led by Xavier and Josep Castells,  CFO and CEO at Inkemia - IUCT respectively, who provide Capital Cell with an enormous investment experience and the largest specialised investor network in Spain.  

Xavier Castells

Xavier Castells

Managing Director, IUCT Emprèn (investment division at Inkemia) 

CFO, Inkemia-IUCT (listed in the MAB, the Spanish alternative stock market)

 

 


Josep Castells

Josep Castells

PhD in Chemistry & founder of 6 ventures
Plasmia Biotech (2010 - currentl)
Inkemia IUCT Group (IUCT Corportion) (2010 - current)
IUCT Espais (2010 - current)
IUCT Empren (2010 - current)
IUCT s.a. (1997 - current)
Catalonia Internet Service Provider - CISP (1996-Sold in 2000)
 

Valuation

Since Capital Cell's investment round in the UK (its "Series A") is currently being negotiated, we currently cannot fix the company's value. Therefore, the investment is being done as a convertible equity loan, which will be converted to shares once the Series A is closed. The valuation will be the one decided then, with a 30% discount (as an indication, the valuation discussed for the series A is 3-5M). 

To learn more about convertible equity loans please watch the following video (in Spanish):

If the Series A didn't finally take place, the shares would be converted to a €1M PreMoney valuation, for a 11.11% of the company. 

Total investment for 2015 will be 200.000 euros, 125.000 of which will be covered by this round, and further 75.000 by a loan. 

 


 

At Capital Cell and at the Spanish CNMV, we want you to know the following: 

This investment round is done through convertible equity loans, and therefore it is a high risk investment, your investment may lose its value if the company has bad results, including among other risks the loss of your capital. Please, be sensible with your money and invest only what you can afford. 

 

We are offering some advices so you can invest with the highest success possible (only in Spanish): consult Capital Cell's guide for investors.

Exit details

Return of Investment

Capital Cell's plan is not to charge for its services in cash, but to keep shares in the companies funded through the platform, which means that in 5 years Capital Cell will have generated around €2.5M in profit, but it will also have a portfolio with shares in over 400 companies.

Return of investment for Capital Cell as a platform is approximately 400% in 5 years, but the projected value of the funded companies is over 800M. Return of investment would come through:

  • sale of Capital Cell to a financial, pharmaceutical or internet company 
  • exit from one of the participated companies
  • sale of the entire investment portfolio
  • and, most of all, you will be able to sell your shares in Capital Cell once its listed in London's stock exchange, starting 2018 

Summarising:

Investing 1 euro in Capital Cell today would bring back between 8.25 and 31.4 euros in 5 years*

* depending on the number of companies funded through Capital Cell that are successful 

¿Any inquiries? Consult Capital Cell's guide for investors or contact us at daniel@capitalcell.net